Neurocrine Announces FDA Conditional Acceptance of Proprietary Name Ingrezza for VMAT2 Inhibitor Valbenazine

SAN DIEGO, Aug. 31, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name Ingrezza for the Company ' s once-daily vesicular...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news